13Jan/14

Zebra Biologics Launched to Commercialize Ground-Breaking Next Gen … – PharmiWeb.com (press release)

Antibodies

Zebra Biologics Launched to Commercialize Ground-Breaking Next Gen …
PharmiWeb.com (press release)
Zebra’s mission is the commercialization of human therapeutic antibodies derived by a novel approach that allows the generation and selection of both agonist and antagonist antibodies from functional screens using a modified combinatorial library approach.
Zebra Biologics launches in SDSan Diego Source (subscription)

all 3 news articles »
13Jan/14

Zebra Biologics Launched to Commercialize Ground-Breaking Next Gen … – 4-traders (press release)

Antibodies

Zebra Biologics Launched to Commercialize Ground-Breaking Next Gen …
4-traders (press release)
Zebra’s mission is the commercialization of human therapeutic antibodies derived by a novel approach that allows the generation and selection of both agonist and antagonist antibodies from functional screens using a modified combinatorial library approach.
Zebra Biologics launches in SDSan Diego Source (subscription)

all 5 news articles »
13Jan/14

Zebra Biologics Launched to Commercialize Ground-Breaking Next Gen … – Business Wire (press release)

Antibodies

Zebra Biologics Launched to Commercialize Ground-Breaking Next Gen …
Business Wire (press release)
Zebra’s mission is the commercialization of human therapeutic antibodies derived by a novel approach that allows the generation and selection of both agonist and antagonist antibodies from functional screens using a modified combinatorial library approach.

and more »
13Jan/14

US FDA Accepts New Drug Application for Gilead's Idelalisib for the Treatment … – Investor's Business Daily

Monoclonal Anti-CD20 Antibodies

Drug Discovery & Development

US FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment …
Investor’s Business Daily
The NDA for iNHL, submitted on September 11, 2013, was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy.
FDA Accepts NDA for Gilead Lymphoma DrugDrug Discovery & Development

all 6 news articles »
12Jan/14

Antibody machinery 'can misfire and cause leukaemia' – BBC News

Antibodies

BBC News

Antibody machinery ‘can misfire and cause leukaemia’
BBC News
The tools used to fortify the body against infection are also one of the causes of the most common form of childhood leukaemia, say researchers. The machinery used to produce millions of antibodies in the immune system can misfire, making cells more …
Immune system development linked to leukemiaMedical Xpress

all 5 news articles »